Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy

被引:30
|
作者
Shi, Binshan [1 ]
Kitchen, Christina [2 ]
Weiser, Barbara [1 ,3 ]
Mayers, Douglas [4 ]
Foley, Brian [5 ]
Kemal, Kimdar [1 ]
Anastos, Kathryn [6 ]
Suchard, Marc [2 ]
Parker, Monica [1 ]
Brunner, Cheryl [1 ]
Burger, Harold [1 ,3 ]
机构
[1] New York State Dept Hlth, Wadsworth Ctr, Div Infect Dis, Albany, NY 12208 USA
[2] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA
[3] Albany Med Coll, Dept Med, Albany, NY 12208 USA
[4] Idenix Pharmaceut Inc, Cambridge, MA 02139 USA
[5] Los Alamos Natl Lab, Los Alamos, NM 87545 USA
[6] Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA
关键词
HIV-1 drug resistance; HIV-1; recombination; tropism; HUMAN-IMMUNODEFICIENCY-VIRUS; FEMALE GENITAL-TRACT; CORECEPTOR USAGE; IN-VIVO; TYPE-1; ENV; V3; LOOP; VIROLOGICAL FAILURE; VIRAL LOAD; POL SEQUENCES; GENOMIC RNA;
D O I
10.1016/j.virol.2010.04.008
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Characterization of residual plasma virus during antiretroviral therapy (ART) is a high priority to improve understanding of HIV-1 pathogenesis and therapy. To understand the evolution of HIV-1 pot and env genes in viremic patients under selective pressure of ART, we performed longitudinal analyses of plasma-derived pol and env sequences from single HIV-1 genomes. We tested the hypotheses that drug resistance in pol was unrelated to changes in coreceptor usage (tropism), and that recombination played a role in evolution of viral strains. Recombinants were identified by using Bayesian and other computational methods. High-level genotypic resistance was seen in similar to 70% of X4 and R5 strains during ART. There was no significant association between resistance and tropism. Each patient displayed at least one recombinant encompassing env and representing a change in predicted tropism. These data suggest that, in addition to mutation, recombination can play a significant role in shaping HIV-1 evolution. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:5 / 20
页数:16
相关论文
共 50 条
  • [21] Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy
    Kearney, Mary F.
    Spindler, Jonathan
    Shao, Wei
    Yu, Sloane
    Anderson, Elizabeth M.
    O'Shea, Angeline
    Rehm, Catherine
    Poethke, Carry
    Kovacs, Nicholas
    Mellors, John W.
    Coffin, John M.
    Maldarelli, Frank
    PLOS PATHOGENS, 2014, 10 (03)
  • [22] Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance
    Grant, Philip M.
    Zolopa, Andrew R.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (08) : 901 - 910
  • [23] Study of HIV-1 Drug Resistance in Patients Receiving Free Antiretroviral Therapy in China
    Xin-ping LI1
    2.State key laboratory for Infectious disease prevention and control
    3.Henan Center for Disease Control and Prevention
    4.Queshan Center for Disease Control and Prevention
    5.Graduate University of Chinese Academy of Sciences
    Virologica Sinica, 2007, (03) : 233 - 240
  • [24] Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy
    Bannister, Wendy P.
    Cozzi-Lepri, Alessandro
    Kjaer, Jesper
    Clotet, Bonaventura
    Lazzarin, Adriano
    Viard, Jean-Paul
    Kronborg, Gitte
    Duiculescu, Dan
    Beniowski, Marek
    Machala, Ladislav
    Phillips, Andrew
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (04) : 901 - 911
  • [25] HIV-1: Gambling on the evolution of drug resistance?
    Andrew J. Leigh Brown
    Douglas D. Richman
    Nature Medicine, 1997, 3 : 268 - 271
  • [26] HIV-1: Gambling on the evolution of drug resistance?
    Brown, AJL
    Richman, DD
    NATURE MEDICINE, 1997, 3 (03) : 268 - 271
  • [27] Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia
    Hudson, F. Parker
    Mulenga, Lloyd
    Westfall, Andrew O.
    Warrier, Ranjit
    Mweemba, Aggrey
    Saag, Michael S.
    Stringer, Jeffrey S. A.
    Eron, Joseph J.
    Chi, Benjamin H.
    ANTIVIRAL THERAPY, 2019, 24 (04) : 291 - 300
  • [28] No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection
    Abdi, Basma
    Thuy Nguyen
    Brouillet, Sophie
    Desire, Nathalie
    Sayon, Sophie
    Wirden, Marc
    Jary, Aude
    Achaz, Guillaume
    Assoumou, Lambert
    Palich, Romain
    Simon, Anne
    Tubiana, Roland
    Valantin, Marc-Antoine
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    Soulie, Cathia
    AIDS, 2020, 34 (12) : 1745 - 1753
  • [29] HIV-1 evolution in relation to molecular epidemiology and antiretroviral resistance
    Skar, Helena
    Hedskog, Charlotte
    Albert, Jan
    EVOLUTION OF INFECTIOUS AGENTS IN RELATION TO SEX, 2011, 1230 : 108 - 118
  • [30] Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile
    Rios, Maritza
    Deliado, Elena
    Perez-Alvarez, Lucia
    Fernandez, Jorge
    Galvez, Paula
    Vazquez de Parga, Elena
    Yung, Veronica
    Thomson, Michael M.
    Najera, Rafael
    JOURNAL OF MEDICAL VIROLOGY, 2007, 79 (06) : 647 - 656